Abstract
Recently, bevacizumab has become a key drug for treatment of metastatic colorectal cancer. Molecularly targeted agents such as bevacizumab can cause life-threatening adverse effects, though they are generally considered less toxic than cytotoxic drugs. Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy. Microscopic findings revealed extensive mucosal necrosis in the resected colon specimen and necrosis at the muscularis propria of the descending colon. Pathological findings suggested that the mucosal damage induced by chemotherapy may be exacerbated by treatment with bevacizumab, resulting in extensive necrosis.
| Original language | English |
|---|---|
| Article number | hyu206 |
| Pages (from-to) | 286-290 |
| Number of pages | 5 |
| Journal | Japanese Journal of Clinical Oncology |
| Volume | 45 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 Mar 1 |
Fingerprint
Keywords
- 5-fluorouracil
- Bevacizumab
- Intestinal perforation
- Metastatic colorectal cancer
- Necrosis
ASJC Scopus subject areas
- Oncology
- Cancer Research
- Radiology Nuclear Medicine and imaging
- Medicine(all)
Cite this
Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient : A case report and review of literature. / Takada, Satoshi; Hoshino, Yoshinori; Ito, Homare; Masugi, Yohei; Terauchi, Toshiaki; Endo, Kazuhiro; Kimata, Masaru; Furukawa, Junji; Shinozaki, Hiroharu; Kobayashi, Kenji; Ogata, Yoshiro.
In: Japanese Journal of Clinical Oncology, Vol. 45, No. 3, hyu206, 01.03.2015, p. 286-290.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient
T2 - A case report and review of literature
AU - Takada, Satoshi
AU - Hoshino, Yoshinori
AU - Ito, Homare
AU - Masugi, Yohei
AU - Terauchi, Toshiaki
AU - Endo, Kazuhiro
AU - Kimata, Masaru
AU - Furukawa, Junji
AU - Shinozaki, Hiroharu
AU - Kobayashi, Kenji
AU - Ogata, Yoshiro
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Recently, bevacizumab has become a key drug for treatment of metastatic colorectal cancer. Molecularly targeted agents such as bevacizumab can cause life-threatening adverse effects, though they are generally considered less toxic than cytotoxic drugs. Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy. Microscopic findings revealed extensive mucosal necrosis in the resected colon specimen and necrosis at the muscularis propria of the descending colon. Pathological findings suggested that the mucosal damage induced by chemotherapy may be exacerbated by treatment with bevacizumab, resulting in extensive necrosis.
AB - Recently, bevacizumab has become a key drug for treatment of metastatic colorectal cancer. Molecularly targeted agents such as bevacizumab can cause life-threatening adverse effects, though they are generally considered less toxic than cytotoxic drugs. Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy. Microscopic findings revealed extensive mucosal necrosis in the resected colon specimen and necrosis at the muscularis propria of the descending colon. Pathological findings suggested that the mucosal damage induced by chemotherapy may be exacerbated by treatment with bevacizumab, resulting in extensive necrosis.
KW - 5-fluorouracil
KW - Bevacizumab
KW - Intestinal perforation
KW - Metastatic colorectal cancer
KW - Necrosis
UR - http://www.scopus.com/inward/record.url?scp=84924730387&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84924730387&partnerID=8YFLogxK
U2 - 10.1093/jjco/hyu206
DO - 10.1093/jjco/hyu206
M3 - Article
VL - 45
SP - 286
EP - 290
JO - Japanese Journal of Clinical Oncology
JF - Japanese Journal of Clinical Oncology
SN - 0368-2811
IS - 3
M1 - hyu206
ER -